MedTrace Logo

Epstein-Barr Virus Antibody and Epstein-Barr Virus DNA for Nasopharyngeal Carcinoma Screening

NCT05447169 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 11625

Last updated 2022-07-08

No results posted yet for this study

Summary

The investigators intend to compare Epstein-Barr virus antibody and Epstein-Barr virus DNA screening efficacy in first-degree relatives of nasopharyngeal carcinoma patients.

Conditions

  • Nasopharyngeal Carcinoma

Interventions

DIAGNOSTIC_TEST

EBV antibodies test

ELISA test of VCA-IgA，EBNA1-IgA，EA-IgA， Zta-IgA ，Rta-IgG and BNLF 2b in nasopharyngeal brushing and plasma

DIAGNOSTIC_TEST

EBV DNA test

quantitative polymerase chain reaction, CRISPR-associated protein 12a and target sequencing of EBV DNA in nasopharyngeal brushing and plasma

Sponsors & Collaborators

  • Wuzhou Red Cross Hospital

    collaborator OTHER

  • Zhongshan People's Hospital, Guangdong, China

    collaborator OTHER

  • Hunan Cancer Hospital

    collaborator OTHER

  • The Third Affiliated Hospital of Nanchang University

    collaborator OTHER

  • First People's Hospital of Foshan

    collaborator OTHER

  • Yuebei People's Hospital

    collaborator OTHER

  • Xiangya Hospital of Central South University

    collaborator OTHER

  • Changsha Central Hospital

    collaborator OTHER

  • Sun Yat-sen University

    lead OTHER

Principal Investigators

  • Ming-Yuan Chen, MD, PhD · Sun Yat-sen University

Eligibility

Min Age
30 Years
Max Age
62 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-10
Primary Completion
2025-07-01
Completion
2030-07-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05447169 on ClinicalTrials.gov